Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
1.730
-0.080 (-4.42%)
At close: Jun 13, 2025, 4:00 PM
1.740
+0.010 (0.58%)
After-hours: Jun 13, 2025, 7:58 PM EDT
Nuvation Bio Employees
Nuvation Bio had 220 employees as of December 31, 2024. The number of employees increased by 169 or 331.37% compared to the previous year.
Employees
220
Change (1Y)
169
Growth (1Y)
331.37%
Revenue / Employee
$49,805
Profits / Employee
-$2,756,286
Market Cap
588.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NUVB News
- 3 days ago - US FDA approves Nuvation Bio's lung cancer therapy - Reuters
- 3 days ago - U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Business Wire
- 24 days ago - Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting - Business Wire
- 4 weeks ago - Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025 - Business Wire
- 4 weeks ago - Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 weeks ago - Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes - Seeking Alpha